Extract
Malignant pleural effusion (MPE) is an indicator of advanced stage malignancy. There are an estimated 150 000 to 200 000 cases of MPE diagnosed annually in the USA [1]. During the past 10 years, the types of cancer treatment and pleural procedures available for MPE have expanded leading to improved stratification and better individualisation of treatment [2]. A recently published prognostic score (PROMISE score) improved prediction of the 3 month risk of death in patients with MPE, thereby improving the selection of appropriate management strategies [3].
Abstract
This novel mouse model mimics malignant pleural effusion drainage using an indwelling pleural catheter in humans, and provides direct access to the pleural space potentially enabling the testing of intrapleural therapies in the treatment of MPE. bit.ly/2W2kzO0
Footnotes
Conflict of interest: C. Merrick has nothing to disclose.
Conflict of interest: T. Sherrill has nothing to disclose.
Conflict of interest: N.I. Kanellakis has nothing to disclose.
Conflict of interest: R. Asciak has nothing to disclose.
Conflict of interest: G.T. Stathopoulos has nothing to disclose.
Conflict of interest: F. Maldonado has nothing to disclose.
Conflict of interest: N.M. Rahman has received consultancy fees from Rocket Medical UK, outside the submitted work.
Conflict of interest: T. Blackwell has nothing to disclose.
Conflict of interest: I. Psallidas works as a Medical Science Director in AstraZeneca in a non-related field.
Support statement: The authors acknowledge support from the US Department of Veterans Affairs. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received November 29, 2018.
- Accepted March 31, 2019.
- Copyright ©ERS 2019
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.